The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.
Scientific title
A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.
Secondary ID [1] 295223 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder 308374 0
Condition category
Condition code
Mental Health 307364 307364 0 0

Study type
Description of intervention(s) / exposure
Extended Release R-107 oral tablets (60 mg). Subjects will be dosed initially with 120mg (2 x 60mg tablets) twice a week. Subjects will be assessed for response at each scheduled clinic visit and may increase the dose to 180mg (3 x 60mg tablets) twice a week or decrease the dose to 60mg (1 x 60mg tablet) twice a week. All participants will be provided with guidance on how and when to take their study drug dose. All participants will also be given a Reminder Card informing them to take the tablets twice a week on days 1 and 4.
Subjects will continue treatment for 24 weeks or until they meet withdrawal criteria. Subjects will be required to returned all study drug bottles for compliance assessments.
A subject will be withdrawn from the study for any of the following reasons:
• Lost to follow-up;
• Withdrawal of consent;
• Violation of protocol procedures (determined on a case by case basis);
• The subject becomes pregnant.

Subjects showing clinically significant worsening of symptoms (as measured through change in MADRS, CADSS, C-SSRS, BPIC-SS score) will be immediately withdrawn from the study if:
• MADRS score greater or equal to 22
• The Principal Investigator sees fit that a subject is withdrawn because of significant tolerability and/or safety issues.
Intervention code [1] 301559 0
Treatment: Drugs
Comparator / control treatment
No control group.
Control group

Primary outcome [1] 306337 0
To evaluate the safety and tolerability of extended release (ER) R-107 tablets in subjects with Refractory Major Depressive Disorder who have completed the R107-C205 (BEDROC) study. Safety and tolerability will be assessed by reviewing adverse events, vital signs and ECGs (assessed centrally by a cardiologist).
Timepoint [1] 306337 0
Primary outcome will be assessed upon completion of the 24 week treatment period.
Secondary outcome [1] 348226 0
Assessment of MADRS score during the open-label study and for 4 weeks post-treatment.
Timepoint [1] 348226 0
MADRS score will be assessed 4-weekly for up to 24-weeks post treatment commencement.

Key inclusion criteria
Subjects must meet all of the following criteria:
1. Provision of written informed consent prior to any study specific procedures
2. Female or male subjects aged 18-81 years inclusive at the time of enrolment (Screening visit).
3. Enrolled into the double-blind treatment phase of the R107-C205 (BEDROC) study.
4. Met relapse criteria at or before Day 92 of the R107-C205 study; or have completed the R107-C205 study.
5. Treatment resistance in major depression defined as lack of clinically meaningful improvement despite the use of adequate doses of at least two antidepressant agents, derived from the group(s) of commonly used first line treatment, prescribed for adequate duration with adequate affirmation of treatment adherence.
Minimum age
18 Years
Maximum age
81 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Subjects must NOT meet any of the following exclusion criteria to be enrolled:
1. Any significant disease or disorder (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient’s ability to participate in the study.
2. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening and at baseline, which in the opinion of the Investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject’s ability to complete entire duration of the study.
3. Any ECG abnormality obtained during the screening period that in Investigator’s judgement may put the patient at risk or negatively affect the outcome of the study.
4. Pregnant, breastfeeding, or lactating women (Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1).
5. Significant current risk of suicide

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis
All safety and tolerability data will be analysed using the Safety Set. The Safety Set will include all subjects who received at least one administration of the study medication. The Open-Label Safety Set will comprise all subjects who received at least one administration of the study medication during the open-label phase.

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 11162 0
Gold Coast University Hospital - Southport
Recruitment hospital [2] 11164 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [3] 11166 0
Epworth Rehabilitation Camberwell - Camberwell
Recruitment hospital [4] 11167 0
Peninsula Private Hospital - Frankston - Frankston
Recruitment hospital [5] 11168 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [6] 12387 0
Black Dog Institute - Randwick
Recruitment hospital [7] 15166 0
Albert Road Clinic - Melbourne
Recruitment hospital [8] 15167 0
Hollywood Private Hospital - Nedlands
Recruitment postcode(s) [1] 22989 0
2050 - Camperdown
Recruitment postcode(s) [2] 28468 0
3004 - Melbourne
Recruitment postcode(s) [3] 22991 0
3124 - Camberwell
Recruitment postcode(s) [4] 22992 0
3199 - Frankston
Recruitment postcode(s) [5] 22987 0
4215 - Southport
Recruitment postcode(s) [6] 22993 0
5112 - Elizabeth Vale
Recruitment postcode(s) [7] 28469 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 10567 0
New Zealand
State/province [1] 10567 0
Auckland, Canterbury, Otago
Country [2] 10568 0
State/province [2] 10568 0

Funding & Sponsors
Funding source category [1] 299813 0
Commercial sector/Industry
Name [1] 299813 0
Douglas Pharmaceuticals Ltd.
Address [1] 299813 0
2 Te Pai Place
Auckland 0610
Country [1] 299813 0
New Zealand
Primary sponsor type
Commercial sector/Industry
Douglas Pharmaceuticals Ltd.
2 Te Pai Place
Auckland 0610
New Zealand
Secondary sponsor category [1] 299163 0
Name [1] 299163 0
Address [1] 299163 0
Country [1] 299163 0

Ethics approval
Ethics application status
Ethics committee name [1] 300693 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 300693 0
Ministry of Health
Health and Disability Ethics Committees
133 Molesworth Street
Wellington 6011
Ethics committee country [1] 300693 0
New Zealand
Date submitted for ethics approval [1] 300693 0
Approval date [1] 300693 0
Ethics approval number [1] 300693 0
Ethics committee name [2] 304746 0
Sydney Local Health District HREC
Ethics committee address [2] 304746 0
Ethics committee country [2] 304746 0
Date submitted for ethics approval [2] 304746 0
Approval date [2] 304746 0
Ethics approval number [2] 304746 0
X18-0476 & HREC/18/RPAH/684

Brief summary
Multi-centre Phase 2a open-labelled extension study of R-107 in MDD treatment resistant subjects who responded to treatment in the R107-C205 (BEDROC) study.

Each subject will participate in up to 3 phases:
• A screening phase of up to 3 weeks
• An open-label treatment phase for 24 weeks
• A 4-week post-treatment (follow up) phase
Trial website
Not Applicable
Trial related presentations / publications
Not Applicable
Public notes
Not Applicable

Principal investigator
Name 84498 0
Prof Paul Glue
Address 84498 0
Department of Psychological Medicine
Dunedin School of Medicine
464 Cumberland Street
Dunedin 9016
Country 84498 0
New Zealand
Phone 84498 0
+64 34740999
Fax 84498 0
Email 84498 0
Contact person for public queries
Name 84499 0
Ms Belinda Williams
Address 84499 0
Douglas Pharmaceuticals Ltd.
2 Te Pai Place
Auckland 0610
Country 84499 0
New Zealand
Phone 84499 0
Fax 84499 0
Email 84499 0
Contact person for scientific queries
Name 84500 0
Dr Jason Long
Address 84500 0
Douglas Pharmaceuticals Ltd.
2 Te Pai Place
Auckland 0610
Country 84500 0
New Zealand
Phone 84500 0
Fax 84500 0
Email 84500 0,nz

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
No decision has been made yet on document sharing/transparency.
What supporting documents are/will be available?
No other documents available
Summary results
No Results